All Trials

A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: First-line study in adults with HER2-negative (or not known positive) unresectable/metastatic gastric/GEJ/esophageal adenocarcinoma (ECOG 0–1) comparing pembrolizumab plus fluoropyrimidine/oxaliplatin chemotherapy versus the same backbone combined with sacituzumab tirumotecan (MK-2870), a TROP2-directed antibody–drug conjugate delivering a belotecan-derived topoisomerase I inhibitor. Safety lead-in determines RP2D, then randomized assessment of response, PFS, and OS.

ClinicalTrials.gov ID: NCT06469944

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic gastric/GEJ/esophageal adenocarcinoma after exactly one prior platinum/fluoropyrimidine regimen (HER2-negative or unknown) are randomized to sacituzumab tirumotecan (TROP2-directed ADC with a topoisomerase I payload) plus paclitaxel versus standard ramucirumab plus paclitaxel. Excludes squamous histology and patients with significant comorbidities (e.g., grade ≥2 neuropathy, ocular surface disease, active CNS mets, recent arterial events, prior VEGF/VEGFR therapy, or prior TROP2/topo I ADCs).

ClinicalTrials.gov ID: NCT06445972

A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, advanced/metastatic gastric/GEJ/esophageal adenocarcinoma (HER2‑negative, MSS/pMMR) in the 2L setting and ESCC in 1L or 2L receive the anti‑CCR8 monoclonal antibody CHS‑114 (depletes intratumoral CCR8+ Tregs via enhanced ADCC/ADCP) plus the PD‑1 inhibitor toripalimab, with cisplatin/5‑FU added in 1L ESCC. Requires measurable disease and tissue; excludes active CNS metastases and prior anti‑CCR8.

ClinicalTrials.gov ID: NCT06657144

Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination With Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors With HER2 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HER2-expressing or HER2-amplified advanced solid tumors (dose escalation) and a dose-expansion focus on CCNE1-amplified, HER2-expressing/amplified gastric/GEJ cancers, T-DXd–naive, receive trastuzumab deruxtecan IV q3w plus the oral WEE1 inhibitor azenosertib on an intermittent schedule. Key exclusions include prior T-DXd or WEE1 inhibitor, significant ILD/pneumonitis risk, and uncontrolled cardiac disease; treated/stable or asymptomatic brain metastases are allowed.

ClinicalTrials.gov ID: NCT06364410

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic clear cell RCC (± sarcomatoid) that recurred during adjuvant anti–PD-(L)1 or within 24 months after completion, without prior VEGF/TKI or HIF-2α therapy, receive oral zanzalintinib (VEGFR2/MET/TAM multi-TKI) plus belzutifan (HIF‑2α inhibitor). Open-label, nonrandomized cohorts explore two zanzalintinib dose levels to assess safety and preliminary efficacy (ORR by BICR).

ClinicalTrials.gov ID: NCT07049926

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: HER2-expressing (IHC 1+/2+/3+) advanced or metastatic endometrial cancer after ≥1 prior systemic therapy, ECOG 0–2; prior anti‑HER2 allowed with reconfirmed HER2, treated/stable CNS disease permitted. Patients receive pembrolizumab plus lenvatinib with an autologous HER2-targeted dendritic cell vaccine (AdHER2DC), with one arm adding N‑803 (IL‑15 superagonist that expands/activates NK and CD8 T cells) to potentially enhance response to PD‑1 blockade; lenvatinib is dose‑de‑escalated to define RP2D.

ClinicalTrials.gov ID: NCT06253494

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-driven platform for adults with recurrent/persistent endometrial carcinoma after 1–2 prior lines, assigning patients by FoundationOne CDx to targeted doublets with or without the PD‑L1 inhibitor atezolizumab. Active cohorts include atezolizumab plus talazoparib for high genomic LOH, atezolizumab plus anti‑TIGIT tiragolumab for MSI‑H/high TMB tumors, inavolisib (PI3Kα inhibitor) plus letrozole for PIK3CA‑mutant tumors without PTEN/AKT1 alterations, and giredestrant (oral SERD) plus abemaciclib for ER‑positive, RB1‑intact disease.

ClinicalTrials.gov ID: NCT04486352

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent clear cell or endometrioid ovarian carcinoma, platinum‑resistant HGSOC (dose‑escalation only), or recurrent FIGO grade 1 endometrioid/clear cell endometrial carcinoma receive oral tuvusertib (ATR inhibitor) plus ZEN‑3694 (pan‑BET inhibitor), with biomarker‑driven expansion enrolling both ARID1A‑mutated and ARID1A‑wild‑type cohorts. Aims include defining RP2D and assessing safety and preliminary activity, with mandated biopsies to explore pharmacodynamic effects and ARID1A‑related response.

ClinicalTrials.gov ID: NCT05950464

Clinical Trial of D2C7-IT + 2141-V11 Combination Immunotherapy Administered Via Convection Enhanced Delivery in Non-enhancing Tumor Post-resection of Recurrent Glioblastoma, Followed by Cervical Perilymphatic Subcutaneous Injections of 2141-V11

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with IDH-wildtype recurrent glioblastoma post–maximal safe resection (with residual non-enhancing T2/FLAIR disease amenable to CED, KPS ≥70) receive intratumoral convection-enhanced delivery of D2C7-IT (EGFR/EGFRvIII-targeted recombinant immunotoxin) combined with 2141‑V11 (Fc‑optimized agonistic anti‑CD40 antibody), followed by serial ipsilateral cervical perilymphatic subcutaneous 2141‑V11 injections. Excludes extensive residual enhancement, brainstem/cerebellar/spinal disease, leptomeningeal or multifocal disease, high-dose steroids, and recent systemic therapy outside washout.

ClinicalTrials.gov ID: NCT06455605

Decentralized Pilot Study of Triple Oral Metronomic Chemotherapy for Patients With Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with recurrent/metastatic oral cavity cancer after or ineligible for standard first-line immunotherapy/chemo-immunotherapy (ECOG 0–2) receive a fully oral metronomic regimen of methotrexate (antifolate), erlotinib (EGFR TKI), and celecoxib (COX‑2 inhibitor) in 28‑day cycles, delivered with decentralized/virtual components. Excludes significant cardiac risk, active serious infection/bleeding, uncontrolled viral hepatitis/HIV, pregnancy, and concurrent investigational therapy.

ClinicalTrials.gov ID: NCT06997068